Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with
cognition. Currently, there are no FDA-approved treatments targeting cognitive function in
Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used
in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as
compared to treatment with a placebo pill in combination with standard anti-inflammatory
drugs in women with MS.
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Recruiting
University of California, Los Angeles
Phase 2
2011-10-01
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with
cognition. Currently, there are no FDA-approved treatments targeting cognitive function in
Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used
in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as
compared to treatment with a placebo pill in combination with standard anti-inflammatory
drugs in women with MS.
MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
Terminated
NeuroCure Clinical Research Center
Phase 2/Phase 3
2013-07-01
In the MOVING study should be examined, whether early therapeutic intervention with
fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a
comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual
evoked potentials (mVEP) after 6 month compared to baseline.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
